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In a recent issue of Clinical Science, Ventura-Clapier et al. highlight a potentially important aspect of 
mitochondrial biology: they may exhibit sexual dimorphism (1). This not-often-considered trait may 
well underlie the sex-related difference in risk to develop a wide range of pathologies. Our knowledge 
of mitochondria has increased vastly in recent times, and we know now that mitochondria are much 
more than simply the “powerhouse of the cell”; mitochondria are now widely recognised to be involved 
in a vast range of cellular processes, and their dysfunction is intrinsically associated with many 
pathologies. 
 
Ventura-Clapier et al. provide an excellent overview of mitochondrial function, and give evidence for 
sexual dimorphism of mitochondrial function in a range of cells and tissues. They elegantly cover a 
wide range of disease states, but we feel the authors have overlooked the opportunity to discuss 
mitochondrial dysfunction and the impact of sex in one of the most mitochondria rich/dense tissues in 
the body, skeletal muscle. Skeletal muscle plays a crucial role in whole-body homeostasis, accounts for 
40% of total protein and 50% of body mass and is indispensable for maintenance of body posture, 
locomotion, respiration, thermoregulation and metabolism. Around 4-7% of the skeletal muscle volume 
consists of mitochondria (2). The significance of skeletal muscle for whole body homeostasis becomes 
particularly apparent in ageing and in pathological conditions such as cachexia, chronic obstructive 
pulmonary disease (COPD) and a wide range of neuromuscular disorders, where loss of skeletal muscle 
mass and function is a key predictor of mortality. Moreover, research has shed light on the potential 
impact of sexual dimorphism on a range of muscle pathologies, where dysfunctional mitochondria 
again, play a central role (3-5). In this editorial, we endeavour to convey the importance of mitochondria 
in skeletal muscle pathologies further evaluating the postulate by Ventura-Clapier et al., to consider 
mitochondrial sexual dimorphism in these conditions.  
 
Mitochondria play an integral role in muscle homeostasis, derived from their fundamental involvement 
in energy metabolism necessary for muscle contraction, mediation of adaptive responses via the 
generation of reactive oxygen and nitrogen species (RONS), regulation of apoptosis, and as a calcium 
sink alongside many other processes (6, 7).  Mitochondrial RONS generation has received considerable 
attention as a key cell signalling molecules (3, 8). Specifically, optimal levels of mitochondrial RONS 
play an important role in modulating multiple signaling pathways and adaptive responses (9, 10), 
whereas elevated levels induce cell death and oxidative damage to cellular components (11). An 
intriguing facet of mitochondria in skeletal muscle is that they are present in two sub-populations: the 
inter-myofibrillar mitochondria located between the myofibrils and the sub-sarcolemmal mitochondria 
in the sub-sarcolemmal regions (12). The inter-myofibrillar mitochondria account for ~80% of total 
mitochondrial density and are primarily responsible for the generation of ATP required for muscle 
contraction (2), whereas the sub-sarcolemmal mitochondria provide ATP for restoring the membrane 
potential following depolarisation and maintaining  cytoplasmic homeostasis (2).  
 
Mitochondria and sexual dimorphism in myopathologies 
We usually consider loss of muscle mass (atrophy), diminished capacity for aerobic ATP generation 
and impaired neuromuscular activation the key tenets of myopathologies. Such changes in muscle 
structure and function can stem from genetic disorders (e.g. Duchenne Muscular Dystrophy), sepsis, 
cancer, disuse, ageing and/or have autoimmune (myositis) and/or neurodegenerative (e.g. Amyotrophic 
lateral sclerosis) origins. Mitochondrial dysfunction contributes to muscle dysfunction in these 
instances, in analogous ways to those reported by Ventura-Clapier et al. in the context of wider 
pathologies.  
 
Ventura-Clapier et al. offer insight into the role of Ca2+ in mediating mitochondrial dysfunction via 
opening of the mitochondrial permeability transition pore (mPTP) and swelling. The authors highlight 
several studies that report that females are more resilient to Ca2+-mediated mitochondrial dysfunction. 
A higher resilience to mitochondrial dysfunction in females has significant implications for 
myopathologies, in particular myositis. Myositis is an acquired autoimmune disease, which causes 
profound muscle weakness, myalgia and disability – a significant unmet clinical need. Patients display 
chronic endoplasmic reticulum (ER) stress in affected muscles, which has been associated with Ca2+ 
leakage from the ER to the mitochondria. The accumulation of Ca2+ induces mitochondrial dysfunction, 
associated with aberrant ROS generation and bioenergetic deficits – both reported to contribute to 
muscle weakness in myositis patients (13, 14). Current research into the mechanisms underpinning 
myositis pays little to no consideration to the impact of sexual dimorphism on muscle weakness, but 
the narrative presented by Ventura-Clapier et al. highlights the importance of stratifying the population 
of myositis patients by sex. 
 
By the time a human reaches their 80s, they will have lost approximately 50% of their muscle mass 
(15), contributing significantly to reductions in strength, locomotion and coordination. The age-related 
loss of muscle mass and function is inevitable and occurs independent of any comorbidities or physical 
activity levels. Despite the large number of studies, there is no consensus on how mitochondrial function 
in skeletal muscle changes during ageing (6, 16-22). Given the evidence summarised by Ventura-
Clapier et al. it is reasonable to hypothesise that sexual dimorphism in mitochondria leads to a higher 
rate of loss of muscle mass in males and females during ageing. In support of this hypothesis, it has 
been observed in rat gastrocnemius muscles that even though they had smaller mass, female muscles 
exhibited higher levels of mitochondrial DNA, mitochondrial complex proteins and antioxidant 
enzymes (23). Many other studies show a higher mitochondrial capacity in muscles from females 
compared to the male in a number of species. These findings may explain at least to some extent the 
higher muscle fatigue resistance and better ability to combat the impact of increased RONS generation 
in male than female muscles (24-27). This is not unequivocal, however, as another study in adult mice 
(10 months) reported no sex differences in mitochondrial bioenergetics, oxidative damage and apoptosis 
(28), or mass –specific aerobic capacity in muscles from men and women (29). Nevertheless, muscle 
mitochondria remain a popular target to counteract the age-related loss of muscle mass and function. 
Administration of SS-31 (a mitochondria-targeted antioxidant) to mice resulted in an overall decrease 
in markers of oxidative damage, improved specific aspects of skeletal muscle mitochondrial function, 
mitophagic potential and organelle integrity. However, SS-31 drug treatment did not attenuate the age-
related myofiber atrophy and reduction in muscle force generation (30). Similarly, a mitochondria-
targeted antioxidant mitoquione mesylate (MitoQ) intervention in old mice failed to rescue the loss of 
muscle mass and function associated with ageing (31). However, it is important to recognise the use of 
a mixed population of both male and female mice in both studies (30, 31). Overall, these observations 
challenge the role of mitochondria-derived RONS in mediating the age-related loss of muscle mass and 
function, suggesting that in contrast to pathologies as suggested by Ventura-Clapier et al., mitochondrial 
dimorphism is unlikely to cause a differential rate of age-related changes in skeletal muscle in males 
and females. 
 
The contrasting observations between many studies are likely attributable to several factors, such as 
species and strain of animal models, and the methodologies used to examine mitochondrial function. 
The latter point is particularly salient and needs to be considered when evaluating the narrative of 
Ventura-Clapier et al. Many studies used isolated mitochondria to assess bioenergetic function. 
However, mitochondria exist in a reticulum, and disruption of this reticulum during isolation alters and 
impairs mitochondrial morphology and function respectively, in contrast to intact or permeabilised 
preparations (17, 32).  Thus, preparations that disrupt the mitochondrial reticulum may well exacerbate 
or mask changes in bioenergetics in a pathology. Therefore, characterising models with different 
methods of preparation is a crucial aspect of gaining a robust understanding of mitochondrial function 
in a wide range of pathologies. 
 
Collectively, the concept of sexual dimorphism in mitochondria is new and it is no surprise that this 
aspect has been given little, if any, attention to explain the differences in muscle function and muscle 
disease susceptibility between men and women. It is questionable whether such a sexual dimorphism 
does exist, particularly when one considers that both males and females derive their mitochondria from 
their mother. Even if mitochondrial sexual dimorphism does exist, it requires more research to establish 
whether it indeed explains or contributes to the different risk and progression of myopathologies 
between men and women. In ageing, for instance, the pattern of muscle loss is similar in males and 
females, and men and women also have similar mitochondrial metabolic activity (29). This does not 
mean, however, that targeting mitochondria therapeutically should not be pursued. Rather, it invites us 
to carefully study whether also in muscle such a sexual dimorphism in mitochondria does contribute to 
different susceptibility to myopathologies in men and women.  
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